Strensiq Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Asfotase alfa

Indications/Uses

Long-term enzyme replacement therapy in patients w/ ped-onset hypophosphatasia (HPP).

Dosage/Direction for Use

SC Perinatal/infantile-onset HPP 2 mg/kg tds wkly or 1 mg/kg 6 times wkly. May be increased to up to 3 mg/kg tds wkly for lack of efficacy (eg, no improvement in resp status, growth or radiographic findings). Juvenile-onset HPP 2 mg/kg tds wkly or 1 mg/kg 6 times wkly.

Contraindications

Hypersensitivity.

MIMS Class

Agents Affecting Bone Metabolism

ATC Classification

A16AB13 - asfotase alfa ; Belongs to the class of enzymes. Used in the treatment of alimentary tract and metabolism problems.

Regulatory Classification

POM

Presentation/Packing

Form

Strensiq soln for inj 100 mg/mL

Packing/Price

1's

Form

Strensiq soln for inj 40 mg/mL

Packing/Price

1's

Strensiq

Manufacturer:

Alexion Pharmaceuticals International Operations